<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001516" GROUP_ID="MOVEMENT" ID="333500021015465377" MERGED_FROM="" MODIFIED="2015-12-16 11:56:43 +0000" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-12-16 10:52:44 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-12-16 10:52:44 +0000" MODIFIED_BY="Ema Roque">
<TITLE>Ropinirole for levodopa-induced complications in Parkinson's disease</TITLE>
<CONTACT>
<PERSON ID="14796" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Carl</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarke</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Clinical Neurology</POSITION>
<EMAIL_1>c.e.clarke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>College of Medical and Dental Sciences</ORGANISATION>
<ADDRESS_1>University of Birmingham</ADDRESS_1>
<ADDRESS_2>Edgbaston</ADDRESS_2>
<CITY>Birmingham</CITY>
<ZIP>B18 7QH</ZIP>
<REGION>West Midlands</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 121 507 4073</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 121 507 5442</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-12-16 10:52:07 +0000" MODIFIED_BY="Ema Roque">
<PERSON ID="14796" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Carl</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarke</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Clinical Neurology</POSITION>
<EMAIL_1>c.e.clarke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>College of Medical and Dental Sciences</ORGANISATION>
<ADDRESS_1>University of Birmingham</ADDRESS_1>
<ADDRESS_2>Edgbaston</ADDRESS_2>
<CITY>Birmingham</CITY>
<ZIP>B18 7QH</ZIP>
<REGION>West Midlands</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 121 507 4073</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 121 507 5442</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11150" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Katherine</FIRST_NAME>
<MIDDLE_INITIALS>HO</MIDDLE_INITIALS>
<LAST_NAME>Deane</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Research Related to Nursing</POSITION>
<EMAIL_1>k.deane@uea.ac.uk</EMAIL_1>
<EMAIL_2>Katherine.deane@unn.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Edith Cavell Building</DEPARTMENT>
<ORGANISATION>University of East Anglia</ORGANISATION>
<ADDRESS_1>Colney Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Norwich</CITY>
<ZIP>NR4 7UL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1603 597047</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1603 597019</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-13 22:25:28 +0000" MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="13" MONTH="11" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="11" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2015-12-16 10:52:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Due to an administrative error, the version of this review that appeared in Issue 3, 2000 of the Cochrane Library had not undergone peer review and was therefore withdrawn in Issue 4. The present text has undergone the full review process of the Movement Disorders Collaborative Review Group.&lt;/p&gt;" NOTES_MODIFIED="2015-12-16 10:52:44 +0000" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-12-16 10:52:44 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>PLS correction</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="13" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="11" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-12-16 10:38:30 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-12-16 10:38:30 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-12-16 10:38:30 +0000" MODIFIED_BY="[Empty name]">Ropinirole for levodopa-induced complications in Parkinson's disease</TITLE>
<SUMMARY_BODY MODIFIED="2015-12-16 10:38:06 +0000" MODIFIED_BY="[Empty name]">
<P>In the later stages of Parkinson's disease, side effects occur because of the use of levodopa treatment. These consist of involuntary writhing movements (dyskinesia), painful cramps in the legs (dystonia) and a shortened response to each dose referred to as 'end-of-dose deterioration' or the 'wearing-off effect'. Dopamine agonist drugs act by mimicking levodopa in the brain, but they do not cause these long-term treatment complications. For this reason, dopamine agonists have for some years been added once these problems develop in the hope of improving them. Ropinirole is a new dopamine agonist recently licensed in the UK for the treatment of early and later Parkinson's disease. In this review, we will examine the trials performed with this drug to see how effective it is and what side effects it causes.</P>
<P>Three trials have compared ropinirole with an inactive placebo in 263 patients in the later stages of Parkinson's disease. Two studies were relatively small, were conducted over the short term (12 weeks), and used relatively low doses of ropinirole (maximum allowed 8 and 10 mg/d) in a twice daily administration regime. For these reasons, the results of these trials have not been included in a statistical overview. The other study was medium term (26 weeks) and used ropinirole doses in line with the current UK licensed maximum (24 mg/d) in a three times a day regime. The conclusions of this review are based on this single trial and thus should be viewed with some caution.</P>
<P>No clear difference in the time patients spent in the immobile off state was found between ropinirole and placebo. However, this was probably due to there being too few patients in the trial. Measurements of physical difficulties and problems with activities of daily living (such as bathing, shopping, etc.) were poor in these studies with incomplete information available. Levodopa dose reduction was greater with ropinirole than placebo by 180 mg/d. However, dyskinesia was increased in those who received ropinirole (2.9 times more common with ropinirole than placebo). No other differences in side effects or withdrawals from treatment were found.</P>
<P>Ropinirole reduces levodopa dose but at the expense of increased dyskinetic side effects. No clear effect on off time reduction was found in this single trial. Side effects were similar with ropinirole and placebo. These conclusions apply to short and medium term treatment, up to 26 weeks. Further longer term trials are required, with measurements of quality of life and costs, and also studies to compare the newer with the older dopamine agonists.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Long-term levodopa therapy for Parkinson's disease is complicated by the development of motor fluctuations and abnormal involuntary movements. One approach is to add a dopamine agonist at this stage of the disease to reduce the time the patient spends immobile or off and to reduce the dose of levodopa in the hope of reducing such problems in the future.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the efficacy and safety of adjuvant ropinirole therapy versus placebo in patients with Parkinson's disease already established on levodopa therapy and suffering from motor complications.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with SmithKline Beecham.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of ropinirole versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data was abstracted independently by the authors and differences settled by discussion. The outcome measures used included Parkinson's disease rating scales, levodopa dosage, 'off' time measurements and the frequency of withdrawals and adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three double-blind, parallel group, randomised, controlled trials have been conducted on 263 patients. The two phase II studies were relatively small, were conducted over the short term (12 weeks), and used relatively low doses of ropinirole (mean administered doses 3.3 and 3.5 mg/d) in a twice daily regime. In view of this clinical heterogeneity and some statistical heterogeneity, the results of these trials have not been included in a meta-analysis. The conclusions of this review are based on the evidence from a single phase III study which was medium term (26 weeks) and used ropinirole doses in line with the current UK licensed maximum in a thrice daily regime.</P>
<P>In view of difficulties in assessing changes in off time in Leiberman 98, caused by the initial imbalance between the arms of the trial, it is unsafe to draw any firm conclusion about the effect of ropinirole on off time. However, as an adverse event, dyskinesia was significantly increased in those who received ropinirole (Leiberman 98; odds ratio 2.90; 1.36, 6.19 95% CI; Table 8). Measurements of motor impairments and disability were poor in this study with incomplete information available. Levodopa dose could be reduced in Leiberman 98 with a significantly larger reduction on ropinirole than on placebo (weighted mean difference 180 mg/d; 106, 253 95% CI; Table 2). No significant differences in the frequency of adverse event reports were noted between ropinirole and placebo apart from the increase in dyskinesia with ropinirole. There was a trend towards fewer withdrawals from ropinirole in Leiberman 98 but this did not reach statistical significance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Ropinirole therapy can reduce levodopa dose but at the expense of increased dyskinetic adverse events. No clear effect on off time reduction was found but this may have been due to the under-powering of the single evaluable trial. Inadequate data on motor impairments and disability was collected to assess these outcomes. These conclusions apply to short and medium term treatment, up to 26 weeks. Further longer term trials are required, with measurements of effectiveness, and also studies to compare the newer with the older dopamine agonists.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-13 22:30:24 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-13 22:30:24 +0000" MODIFIED_BY="[Empty name]">
<P>Over 20 years after its introduction, levodopa remains the most effective therapy in Parkinson's disease. However, with long-term treatment, patients develop side effects comprised of motor and psychiatric complications. The former consist of involuntary writhing movements of the limbs and trunk (choreoathetosis), painful cramps often affecting the feet (dystonia) and a shortened response to each dose of levodopa (end-of-dose deterioration). These affect 50% of patients after 6 years of therapy (<LINK REF="REF-Rajput-1984" TYPE="REFERENCE">Rajput 1984</LINK>) and 100% of young onset patients (<LINK REF="REF-Quinn-1986" TYPE="REFERENCE">Quinn 1986</LINK>).</P>
<P>An alternative treatment in Parkinson's disease is the dopamine agonist class of drug. These act directly on post-synaptic dopamine receptors in the striatum and so they do not require conversion into dopamine, as does levodopa. They have developed the reputation of being less effective in clinical practice than expected, although they generate fewer motor complications when used as long-term monotherapy (e.g. <LINK REF="REF-PDRG-1993" TYPE="REFERENCE">PDRG 1993</LINK>). The use of dopamine agonists in newly diagnosed patients will be the subject of further Cochrane reviews.</P>
<P>Ropinirole is a non-ergot based dopamine agonist like pramipexole but unlike the ergot-based bromocriptine, pergolide, lisuride, and cabergoline. Trials in early and late Parkinson's disease have lead to it receiving a product licence in the United Kingdom for both indications. Monotherapy studies will be the subject of other Cochrane reviews.</P>
<P>This systematic review will examine all randomised controlled trials comparing ropinirole with placebo in later Parkinson's disease with motor complications to evaluate its efficacy and safety. Another review will deal with trials comparing ropinirole with bromocriptine.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the efficacy and safety of adjuvant ropinirole therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised trials comparing adjuvant ropinirole with placebo were considered for inclusion in the study.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a clinical diagnosis of idiopathic Parkinson's disease who had developed long-term motor complications of dyskinesia and/or end-of-dose deterioration. All ages were included. Any duration of levodopa therapy was included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral ropinirole therapy or placebo. Trial durations of greater than 4 weeks were included. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Improvement in the time patients spend in the immobile 'off' state.</P>
<P>2. Changes in dyskinesia rating scales and the prevalence of dyskinesia.</P>
<P>3. Changes in parkinsonian rating scales.</P>
<P>4. Reduction in levodopa dose.</P>
<P>5. Number of withdrawals due to lack of efficacy and/or side-effects.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. The review was based on the search strategy of the Movement Disorders Group. This included computerised searches of MEDLINE and EMBASE and hand searching of appropriate neurology journals. Relevant trials were included on the Group's specialised register of randomised controlled trials. Further details are available in the Group's module on the Cochrane Database of Systematic Reviews.</P>
<P>2. The Cochrane Controlled Trials Register was also searched for relevant trials.</P>
<P>3. The reference lists of located trials and of other ropinirole reviews were searched.</P>
<P>4. Additional assistance was provided by the drug manufacturer SmithKline Beecham.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The two authors (CC, KD) independently assessed the studies identified by the search strategy. Disagreements about inclusions were resolved by discussion. The full papers were assessed for methodological quality by recording the method of randomisation and blinding, whether an intention to treat analysis was used and the number of patients lost to follow up.</P>
<P>Eligible data was abstracted onto standardised forms by the authors independently, checked for accuracy and amalgamated. A weighted estimate (fixed effect model) of the typical treatment effect across trials was calculated for continuous (weighted mean difference) and dichotomous (Peto odds ratio) variables such as 'off' time and prevalence of adverse events.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<P>See also Characteristics of Included Studies.</P>
<P>Three trials meeting the inclusion criteria were located. Two of these have been published (<LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>; <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>) but one unpublished trial was provided by the manufacturer (<LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>).</P>
<P>A total of 263 patients were included in these placebo controlled studies and 164 were randomised to ropinirole. All of the trials were randomised, double-blind, parallel group design.</P>
<P>Details of age, sex, and severity of disease (Hoehn and Yahr scale) were given for both arms of most of the trials. No major differences at baseline were apparent.</P>
<P>Two trials were short phase II studies which used a bid ropinirole dosing regime up to a maximum of 8 mg/d (<LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>) and 10 mg/d (<LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>). The remaining study was a large phase III trial using the now licensed maximum ropinirole dose of 24 mg/d in a tds regime (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>). The mean dose of ropinirole at the end of titration achieved was only given in one study (3.3 mg/d; <LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>). Levodopa dose reduction was not allowed in one trial (<LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<P>See also Characteristics of Included Studies.</P>
<P>Randomisation was performed using a computer generated schedule for all three studies. Concealment of allocation was guaranteed by coded supplies being sent to investigators.</P>
<P>All studies were double-blind making performance and attrition bias unlikely, although <LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK> was analysed on a per protocol basis so attrition from the study may have been biased by the allocated treatment.</P>
<P>The statistician analysing the results were not blinded, but an analysis plan was agreed before the blind was broken. This, combined with the double-blind design, meant detection bias was unlikely.</P>
<P>
<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> was a phase III study lasting 26 weeks and used doses of ropinirole up to 24 md/d. In comparison the two phase II studies lasted only 12 weeks and used doses of ropinirole which are now considered to be sub-optimal: up to a maximum dose of 8 mg/d in <LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK> (mean dose actually administered 3.3 mg/d) and 10 mg/d in <LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK> (mean dose actually administered 3.5 mg/d).</P>
<P>Sample size calculations were either not presented in the trial publications or reports or only in a partial form, although the manufacturers have provided further details to the authors of this review.</P>
<P>Two of these studies used composite outcome measures. In <LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>, the primary outcome was whether patients had made a 20% or greater decrease in their levodopa dose. In <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> this was even more complex: patients were classified as responders if they achieved a 20% reduction in levodopa dose AND a 20% reduction in off time. Presenting the results in this manner makes it difficult to compare them with the results of other trials which traditionally do not use such an approach. Although it is common to see percentage improvements in off time and levodopa dose reported, it is often more appropriate to use the actual off time reduction in minutes and levodopa dose reduction in milligrammes. The latter approach has the advantage that the outcome means something, both to clinicians and more importantly patients. To unravel these composite outcomes, additional data has been provided by the manufacturer.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<P>See also <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>Key Characteristics and Results for Included Studies and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> Adverse Events for Included Studies.</P>
<P>Ropinirole has been compared with placebo in three studies which were all randomised controlled trials conducted on a double-blind, parallel group basis. A total of 263 patients were included in the studies, of which 164 were randomised to ropinirole. The two phase II studies were relatively small, were conducted over the short term, and used relatively low doses of ropinirole in a twice daily regime (<LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>; <LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>). The other phase III study was medium term and used ropinirole doses in line with the current UK licensed maximum in a thrice daily regime (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>).</P>
<P>The reporting of outcome measures was complicated in two studies by the use of composites of several measurements (see Methodological Quality of Included Studies). To circumvent this, additional data has been secured from the manufacturer which allows some quantitative analysis of continuous variables using their original units.</P>
<P>In the two phase II trials (<LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>; <LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>), the very low doses of ropinirole used, the twice daily admininstration regime, and the small numbers of patients treated strongly suggest that the results of these studies are unreliable in comparison with the larger phase III study. Added to this clinical heterogeneity is the finding of statistical heterogeneity if meta-analysis of levodopa dose reduction and all cause withdrawal rates is performed. It is therefore appropriate to present the data from the phase II trials for open scrutiny but inappropriate to perform a formal statistical overview. Whilst the single phase III trial (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>) suffered from significant problems, which are discussed in detail below, the results of this trial are likely to be more reliable and conclusions about the efficacy and safety of ropinirole compared with placebo should be based on this work.</P>
<P>The effect of ropinirole on off time in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> presents a more complex situation than that seen with the other dopamine agonists. The authors of the original report compared the proportion of patients who achieved a 20% or greater reduction in off time AND a 20% or greater reduction in levodopa dose. This composite outcome was achieved by 35% of those given ropinirole compared with only 13% with placebo which was statistically significant (p = 0.003). We have used additional data supplied by the manufacturer to express the change in off time in hours in Table 3. The difference in the reduction in off time in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> was greater with ropinirole than placebo but this did not reach statistical significance (weighted mean difference [WMD] 0.31 hours; -1.02, 1.64 95% CI; Table 3). On reporting this to the manufacturer, before the final peer review process, they re-examined the original off time data and discovered that the number of hours spent in the off phase in the ropinirole and placebo groups was significantly different at the start of the study. They went on to perform an Analysis of Covariance (ANOCOVA) on the intention-to-treat data using each patient's baseline off time as a covariate. This yielded a reduction in off time of 1.2 hours more with ropinirole than placebo which was statistically significant (0.04, 2.32 95% CI; p = 0.04). However, the residuals from this analysis were non-normal indicating a violation of the assumptions of the ANOCOVA and suggesting that a non-parametric methodology should be used. ANOCOVA of the ranked data continued to show a significant difference in favour of ropinirole (p &lt; 0.01).</P>
<P>In the light of the disparate results of the analyses above and particularly the imbalance in off time in the two arms of the trial at baseline, it is unsafe to draw any firm conclusions regarding the efficacy of ropinirole for this outcome measure. However, it seems likely that if <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> had been larger, that baseline imbalance would not have occurred and that an unequivocal benefit in off time with ropinirole would have been found.</P>
<P>Dyskinesia was not measured with rating scales in any of these trials. However, data on dyskinesia reported as a new adverse event during the phase III trial (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>) was given. It was significantly increased in those who received ropinirole (odds ratio [OR] 2.90; 1.36, 6.19 95% CI; Table 8).</P>
<P>The reporting of measurements of motor impairments and disability was poor in these studies but additional data has been secured from the manufacturer. In <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>, there were significantly more patients 'much' or 'very much' improved on ropinirole compared with placebo (OR 2.98; 1.53, 5.80; p = 0.001; Table 1) using a standard seven point rating scale. </P>
<P>Levodopa dose could be reduced in two studies (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>; <LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>). In <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>, the dose could be reduced significantly more with ropinirole than with placebo (WMD 180 mg/d; 106, 253 95% CI; Table 2).</P>
<P>No significant differences in the frequency of adverse event reports were noted between ropinirole and placebo in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> apart from the increase in dyskinesia with ropinirole (Tables 4 to 10 and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). There was a trend towards fewer withdrawals from ropinirole in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> but this did not reach statistical significance (OR 0.52; 0.24, 1.09 95% CI; Table 11).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<P>The three randomised controlled trials comparing ropinirole with placebo involved only 263 patients. In the phase III study (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>), 149 of these patients received the trial agent for 26 weeks, whereas in the two phase II trials treatment continued for only 12 weeks (<LINK REF="STD-Korcyn-1990" TYPE="STUDY">Korcyn 1990</LINK>; <LINK REF="STD-Rascol-1996" TYPE="STUDY">Rascol 1996</LINK>). The small patient numbers, the use of sub-optimal doses of ropinirole, and the twice daily administration regimes in the two phase II trials led to significant clinical and statistical heterogeneity so their inclusion in a formal meta-analysis might lead to unsafe conclusions about the comparative efficacy and safety of ropinirole. Therefore, formal statistical overview of the phase II studies has not been performed and conclusions will be based on the findings of the phase III study (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>) only. Even then, the latter study was relatively small which led to imbalance in off time between the ropinirole and placebo groups at baseline. So here too, the results should be viewed cautiously.</P>
<P>In view of the difficulties in assessing the changes in off time in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>, caused by the initial imbalance between the arms of the trial, it is unsafe to draw any firm conclusion about the effect of ropinirole on off time. It must be stressed that absence of evidence does not imply absence of effect and the evidence available suggests that if larger numbers of patients had been included in <LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK> an unequivocal result would have been gained. This is corroborated by the significant increase in dyskinesia with ropinirole as measured as an adverse event (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>; OR 2.90; 1.36, 6.19 95% CI; Table 8). This occurred in spite of significant levodopa dose reduction (<LINK REF="STD-Leiberman-1998" TYPE="STUDY">Leiberman 1998</LINK>; WMD180 mg/d; 106, 253 95% CI; Table 2). Insufficient information was recorded on motor impairments and disability to be able to assess these outcomes reliably. No significant difference in adverse events occurred apart from dyskinesia (Tables 4 to 10) and withdrawal rates were not significantly different between ropinirole and placebo.</P>
<P>In summary, the comparatively small amount of trial data comparing ropinirole with placebo does not show a clear advantage for ropinirole in terms of off time reduction and motor impairment and disability. However, ropinirole does allow a reduction in levodopa dose but at the expense of increased dyskinetic adverse events.</P>
<P>A number of general criticisms of these trials can be made:-</P>
<UL>
<LI>All such trials should be published in one format or another so that the information is in the public domain and to reduce publication bias.</LI>
<LI>The standard of trial reporting must be improved, preferably using CONSORT guidelines (Consolidated Standards of Reporting Trials; <LINK REF="REF-CONSORT-1996" TYPE="REFERENCE">CONSORT 1996</LINK>).</LI>
<LI>Sample size calculations should be performed and reported for all phase III studies.</LI>
<LI>Complex derivations of outcome measures should be discouraged; it is often preferable to use the original units, especially if these are more informative to clinicians and patients.</LI>
</UL>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>As an adjuvant therapy over the medium term, ropinirole is effective in reducing levodopa dose but at the expense of increased dyskinetic adverse events. No clear effect on off time reduction was found but this may have been due to under-powering of the trials and the low doses of ropinirole used in the phase II studies. Inadequate data on motor impairments and disability was collected to assess these outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<P>Incomplete reporting<BR/>To aid the evaluation of similar trials in the future it is suggested that:-</P>
<UL>
<LI>All completed trials should be published in one form or another to prevent publication bias.</LI>
<LI>Trial reporting must be improved by using the CONSORT guidelines (<LINK REF="REF-CONSORT-1996" TYPE="REFERENCE">CONSORT 1996</LINK>).</LI>
<LI>Outcome measure reports must include details of standard deviation or standard error and the numbers of patients evaluated.</LI>
<LI>Composite outcomes should be avoided; analysis and reporting should be performed using the original units.</LI>
<LI>Sample size calculations should be performed and reported for all phase III studies.</LI>
</UL>
<P>
<BR/>Further Trials<BR/>Previous Cochrane reviews have examined placebo-controlled trials of bromocriptine, lisuride, pergolide, and pramipexole adjuvant therapy in Parkinson's disease and the last three of these in comparison with bromocriptine therapy. Other reviews will compare ropinirole versus bromocriptine and cabergoline versus placebo and bromocriptine.</P>
<P>Direct comparison of the efficacy, effectiveness, and safety of all of these dopamine agonists would require a very large international study. Without such an undertaking, clinicians must continue to choose which agonist to use as adjuvant therapy according to other properties such as familiarity, dose frequency, and price.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank SmithKline Beecham for their assistance in performing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>CEC has taken part in clinical trials with ropinirole. He has received payment from SmithKline Beecham for lectures, for attending meetings, and for serving on advisory boards.</P>
<P>This review was submitted to SmithKline Beecham for comments at the peer review stage. The comments of the manufacturer which agreed with independent peer review were reflected in a further iteration of this review. This then underwent further formal peer review before publication.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CEC instigated and arranged funding for the review. Both authors performed the search strategy, the data abstraction, and the analysis of the data. Both authors wrote the review and will act as guarantors for the accuracy of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Korcyn-1990" MODIFIED="2008-11-13 22:27:22 +0000" MODIFIED_BY="[Empty name]" NAME="Korcyn 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Korcyn et al</AU>
<TI>Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in Parkinsonian patients not optimally controlled in L-dopa</TI>
<SO>SmithKline Beecham Pharmaceuticals Report No: MY-1002/SKF-101468/2/CPMS-034.</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leiberman-1998" MODIFIED="2008-11-13 22:27:32 +0000" MODIFIED_BY="[Empty name]" NAME="Leiberman 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kreider MM, Knox S, Gardiner D, Wheadon D</AU>
<TI>A multicentre double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease</TI>
<SO>ANN, 48th Annual Meeting</SO>
<YR>1996</YR>
<PG>S67.003</PG>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreider MS, Knox S, Gardiner D, Wheadon DE</AU>
<TI>The efficacy of ropinirole, a non-ergoline D2 agonist, as an adjunct to L-dopa (DCI) in patients with Parkinson's disease</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Supplement 1</NO>
<PG>156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman A, Olanow C, Sethi K, et al</AU>
<TI>A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>1057-1062</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rascol-1996" MODIFIED="2008-11-13 22:27:40 +0000" MODIFIED_BY="[Empty name]" NAME="Rascol 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D</AU>
<TI>Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>234-245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-CONSORT-1996" MODIFIED="2008-11-13 22:27:57 +0000" MODIFIED_BY="[Empty name]" NAME="CONSORT 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF.</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement.</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-639</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PDRG-1993" NAME="PDRG 1993" TYPE="JOURNAL_ARTICLE">
<AU>Parkinson's Disease Study Group in the United Kingdom</AU>
<TI>Comparison of the therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>469-472</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quinn-1986" NAME="Quinn 1986" TYPE="JOURNAL_ARTICLE">
<AU>Quinn N, Critchley P, Parkes D, Marsden CD</AU>
<TI>When should levodopa be started?</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>ii</VL>
<PG>985-986</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajput-1984" NAME="Rajput 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rajput AH, Stern W, Laverty WH</AU>
<TI>Chronic low-dose levodopa therapy in Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>991-996</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Korcyn-1990">
<CHAR_METHODS>
<P>Randomised, double-blind, parallel group design.<BR/>Randomisation by computer generated random numbers. Patients allocated in a 2:1 ratio with ropinirole or placebo respectively.<BR/>Data was analysed on a per protocol basis.<BR/>Location: 6 centres in UK, 2 in Israel.<BR/>Duration: 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ropinirole: 46 patients with 15 drop-outs (33%).<BR/>Placebo: 22 patients with 4 drop-outs (18%)<BR/>Age: Ropinirole 62.3 years, placebo 63.7 years.<BR/>Hoehn and Yahr score at baseline: Ropinirole 2.9, placebo 2.8.<BR/>Inclusion criteria: IPD patients not optimally controlled on levodopa. NB. No details of motor complications.<BR/>No Exclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ropinirole: Initial dose = 1mg/d, maximum = 10mg/d. Ropinirole taken b.i.d.<BR/>Levodopa could be reduced after week 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Responders = &gt;20% decrease in l-dopa dose.<BR/>Secondary: On/Off diary<BR/>Clinicians Global Evaluation<BR/>UPDRS motor subsection<BR/>Finger taps</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leiberman-1998">
<CHAR_METHODS>
<P>Randomised, double-blind, parallel group design.<BR/>Randomised according to a computer generated schedule to treatment with either ropinirole or placebo in a 2:1 ratio. Patients were stratified as to whether they were taking selegiline because of the potential for selegiline to decrease the need for L-dopa.<BR/>Data analysed on an intention to treat basis (last observation carried forward).<BR/>Location: 16 sites, USA.<BR/>Duration: 26 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ropinirole: 95 patients with 21 drop-outs (22%).<BR/>Placebo: 54 patients with 19 drop-outs (35%).<BR/>The ages of the patients were not provided.<BR/>The mean Hoehn and Yahr score at baseline was 2.8 for both groups.<BR/>Inclusion criteria: IPD with motor complications.<BR/>Exclusion criteria: Complex complications, serious cardiac problems, liver or renal disease, dementia, psychosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Medication given three times daily. Initial dose 0.75mg/d increased by 0.75mg/d over 2 weeks to 3mg/d, then increased by 1.5mg/d per week to 9mg/d, then increased by 3.0mg/d per week to a maximum of 24mg/d. The minimum dose was 7.5mg/d. The mean dose was not given.<BR/>Levodopa could be reduced once patient titrated to 7.5mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Responders = 20% reduction in l-dopa and 20% reduction in 'off' time (composite outcome).<BR/>Secondary: Clinicians global impression scale<BR/>On/off chart (60 min epochs)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rascol-1996">
<CHAR_METHODS>
<P>Randomised, double-blind, parallel group design.<BR/>Randomisation by computer generated random numbers.<BR/>Intention to treat analysis and analysis of 'efficacy evaluable' population (those who fulfilled major compliance criteria).<BR/>Location: 2 sites, UK and France.<BR/>Duration: 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ropinirole: 23 patients with 2 drop-outs (9%)<BR/>Placebo: 23 patients with 9 drop-outs (39%)<BR/>Details of terminations given.<BR/>Mean age: ropinirole = 62 (SD7), placebo = 63 (SD9).<BR/>Hoehn and Yahr score at baseline: ropinirole = 2.8, placebo = 3.0.<BR/>Inclusion criteria: IPD with motor complications, on 3-7 doses of L-dopa per day.<BR/>Exclusion criteria: Hoehn and Yahr score of 5, psychosis, dementia, other CNS disorders, apomorphine therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Medication taken twice daily. Initial dose of 1.0mg/d increased by 0.5mg increments to a maximum of 8.0mg/d. Mean dose 3.3mg/d.<BR/>Levodopa dose remained constant throughout trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>On/Off diaries (60 min epochs)<BR/>Clinicians global impression score (5 point scale)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Korcyn-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leiberman-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rascol-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Key Characteristics and Results for Included Studies</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Number of patients</P>
</TD>
<TD>
<P>Mean Hoehn &amp; Yahr</P>
</TD>
<TD>
<P>Duration (weeks)</P>
</TD>
<TD>
<P>Mean (Maximum) Dose Ropinirole (mg/d)</P>
</TD>
<TD>
<P>Mean difference (MD) L-dopa reduction (mg/d; + in favour of ropinirole)</P>
</TD>
<TD>
<P>MD off hours reduction (hours; + in favour of ropinirole)</P>
</TD>
</TR>
<TR>
<TD>
<P>Korcyn</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>(10)</P>
</TD>
<TD>
<P>25.60</P>
</TD>
<TD>
<P>0.58</P>
</TD>
</TR>
<TR>
<TD>
<P>Leiberman</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>(24)</P>
</TD>
<TD>
<P>179.61</P>
</TD>
<TD>
<P>0.31</P>
</TD>
</TR>
<TR>
<TD>
<P>Rascol</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>3.3 (8)</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>-0.48</P>
</TD>
</TR>
<TR>
<TD>
<P>Total</P>
</TD>
<TD>
<P>263</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Adverse Events for Included Studies (Peto Odds Ratio &lt; 1 favours ropinirole)</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Study (number)</P>
</TD>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>Postural Hypotension</P>
</TD>
<TD>
<P>Hallucinations</P>
</TD>
<TD>
<P>Confusion</P>
</TD>
<TD>
<P>Dyskinesia</P>
</TD>
<TD>
<P>Insomnia</P>
</TD>
<TD>
<P>Somnolence</P>
</TD>
<TD>
<P>All cause withdrawals</P>
</TD>
</TR>
<TR>
<TD>
<P>Korcyn (68)</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>2.03</P>
</TD>
</TR>
<TR>
<TD>
<P>Leiberman (149)</P>
</TD>
<TD>
<P>1.88</P>
</TD>
<TD>
<P>0.89</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>2.90</P>
</TD>
<TD>
<P>0.61</P>
</TD>
<TD>
<P>1.78</P>
</TD>
<TD>
<P>0.52</P>
</TD>
</TR>
<TR>
<TD>
<P>Rascol (46)</P>
</TD>
<TD>
<P>2.72</P>
</TD>
<TD>
<P>3.73</P>
</TD>
<TD>
<P>0.50</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>1.88</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>3.27</P>
</TD>
<TD>
<P>0.19</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Ropinirole versus Placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="56" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Clinicians global impression scale (number improved)</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.798791681678734" CI_START="1.5307529387560965" EFFECT_SIZE="2.9793484871636164" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="17" LOG_CI_END="0.7633375072440847" LOG_CI_START="0.1849051018718282" LOG_EFFECT_SIZE="0.4741213045579565" ORDER="35273" O_E="9.456375838926178" SE="0.33977405820224854" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="8.662027641803327" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="135" TOTAL_2="76" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Levodopa dose reduction (mg)</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="142.9354305824054" CI_START="-91.73543058240539" EFFECT_SIZE="25.599999999999994" ESTIMABLE="YES" MEAN_1="157.03" MEAN_2="131.43" ORDER="35274" SD_1="259.71" SD_2="206.53" SE="59.866115657191806" STUDY_ID="STD-Korcyn-1990" TOTAL_1="41" TOTAL_2="22" WEIGHT="0.0"/>
<CONT_DATA CI_END="252.74005252557873" CI_START="106.47994747442131" EFFECT_SIZE="179.61" ESTIMABLE="YES" MEAN_1="235.93" MEAN_2="56.32" ORDER="35275" SD_1="246.71" SD_2="200.53" SE="37.31193690415703" STUDY_ID="STD-Leiberman-1998" TOTAL_1="94" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="155" TOTAL_2="98" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Off time reduction (hours)</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.952537087857791" CI_START="-0.7925370878577909" EFFECT_SIZE="0.5800000000000001" ESTIMABLE="YES" MEAN_1="1.33" MEAN_2="0.75" ORDER="35276" SD_1="2.35" SD_2="2.81" SE="0.700286892353221" STUDY_ID="STD-Korcyn-1990" TOTAL_1="42" TOTAL_2="22" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.6419677373006183" CI_START="-1.0219677373006182" EFFECT_SIZE="0.31000000000000005" ESTIMABLE="YES" MEAN_1="1.53" MEAN_2="1.22" ORDER="35277" SD_1="4.28" SD_2="3.7" SE="0.6795878637602577" STUDY_ID="STD-Leiberman-1998" TOTAL_1="90" TOTAL_2="53" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.0799403337807107" CI_START="-2.039940333780711" EFFECT_SIZE="-0.4800000000000002" ESTIMABLE="YES" MEAN_1="1.74" MEAN_2="2.22" ORDER="35278" SD_1="2.36" SD_2="3.0" SE="0.795902550294455" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="118" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Nausea</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.586919663912561" CI_START="0.772148895893277" EFFECT_SIZE="1.8819630586282095" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.6615211338915201" LOG_CI_START="-0.1122989452216701" LOG_EFFECT_SIZE="0.27461109433492503" ORDER="35279" O_E="3.0604026845637584" SE="0.4545457449422566" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="4.83999381571563" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.868881786884078" CI_START="0.6798359061966546" EFFECT_SIZE="2.7182818284590455" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0361848652669305" LOG_CI_START="-0.16759590146042688" LOG_EFFECT_SIZE="0.43429448190325187" ORDER="35280" O_E="2.0" SE="0.7071067811865476" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="2.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="118" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Postural hypotension</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.141568849713023" CI_START="0.37056188309307736" EFFECT_SIZE="0.8908331974747761" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.33073204117470534" LOG_CI_START="-0.43113925531853836" LOG_EFFECT_SIZE="-0.050203607071916484" ORDER="35281" O_E="-0.5771812080536911" SE="0.4475269708838721" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="4.9930000718253496" WEIGHT="0.0"/>
<DICH_DATA CI_END="23.421229684227647" CI_START="0.5948199519114916" EFFECT_SIZE="3.732481040069767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3696096930871056" LOG_CI_START="-0.22561447246390576" LOG_EFFECT_SIZE="0.5719976103115999" ORDER="35282" O_E="1.5" SE="0.9370425713316364" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="1.138888888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Hallucinations</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.040628502531826" CI_START="0.04914994190413674" EFFECT_SIZE="0.4977414972249903" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7024846908430847" LOG_CI_START="-1.3084769911732035" LOG_EFFECT_SIZE="-0.30299615016505943" ORDER="35283" O_E="-0.5" SE="1.1812488464372366" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="0.7166666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Confusion</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.49617446289731" CI_START="0.06062011542428635" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2173832410452208" LOG_CI_START="-1.2173832410452208" LOG_EFFECT_SIZE="0.0" ORDER="35284" O_E="0.0" SE="1.4301938838683885" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="0.48888888888888893" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="118" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Dyskinesia</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.1870417530881" CI_START="1.3604593880486924" EFFECT_SIZE="2.901244394606898" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" LOG_CI_END="0.7914830468547477" LOG_CI_START="0.13368558190438032" LOG_EFFECT_SIZE="0.46258431437956404" ORDER="35285" O_E="7.134228187919462" SE="0.3863934870618118" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="6.69792692561937" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.67879672666213" CI_START="0.5271887781145269" EFFECT_SIZE="1.8764292381020686" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8246982256428482" LOG_CI_START="-0.2780338428275662" LOG_EFFECT_SIZE="0.273332191407641" ORDER="35286" O_E="1.5" SE="0.6477502756312957" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="2.3833333333333337" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Insomnia</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5130726836152046" CI_START="0.24731384560826988" EFFECT_SIZE="0.6117220153547699" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.1798597907692702" LOG_CI_START="-0.6067515694334892" LOG_EFFECT_SIZE="-0.2134458893321095" ORDER="35287" O_E="-2.302013422818792" SE="0.46205940677213214" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="4.68386498295061" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="118" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - Somnolence</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.400142602188903" CI_START="0.7192094602964001" EFFECT_SIZE="1.7789390619544783" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.6434667515635022" LOG_CI_START="-0.14314460863925732" LOG_EFFECT_SIZE="0.25016107146212246" ORDER="35288" O_E="2.697986577181208" SE="0.46205940677213214" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="4.68386498295061" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.76664602563215" CI_START="0.723286450684856" EFFECT_SIZE="3.2681057192812957" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1692818644406313" LOG_CI_START="-0.14068967045924557" LOG_EFFECT_SIZE="0.5142960969906929" ORDER="35289" O_E="2.0" SE="0.7694837640638655" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="1.6888888888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="164" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>All cause withdrawal rate</NAME>
<GROUP_LABEL_1>Ropinirole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.233306698936229" CI_START="0.6584270730216788" EFFECT_SIZE="2.025877065625406" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.7947184961168786" LOG_CI_START="-0.18149232022866013" LOG_EFFECT_SIZE="0.30661308794410935" ORDER="35290" O_E="2.1470588235294112" SE="0.5734310658428451" STUDY_ID="STD-Korcyn-1990" TOTAL_1="46" TOTAL_2="22" VAR="3.0411480658988794" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0937993536420243" CI_START="0.2434680896781087" EFFECT_SIZE="0.5160477101222073" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.038937662401405525" LOG_CI_START="-0.6135579518409654" LOG_EFFECT_SIZE="-0.28731014471978" ORDER="35291" O_E="-4.503355704697988" SE="0.38327915371135046" STUDY_ID="STD-Leiberman-1998" TOTAL_1="95" TOTAL_2="54" VAR="6.807217108554886" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7436298486146367" CI_START="0.050970135843216476" EFFECT_SIZE="0.19468670833151025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.12864318637127609" LOG_CI_START="-1.292684208948457" LOG_EFFECT_SIZE="-0.7106636976598665" ORDER="35292" O_E="-3.5" SE="0.6837634587578276" STUDY_ID="STD-Rascol-1996" TOTAL_1="23" TOTAL_2="23" VAR="2.1388888888888893" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>UPDRS Motor Score</NAME>
<TR>
<TH/>
</TR>
<OTHER_DATA ORDER="21" STUDY_ID="STD-Korcyn-1990">
<TR>
<TD>
<P>Either on or off state: Improvement on ropinirole -2.21 (n 46; SD 9.72) v placebo -7.41 (n 22; SD 7.28)<BR/>p &gt; 0.05; NS.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>